Regeneron Reports Shareholder Vote Results
Summary
Regeneron Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders on June 12, 2026, where shareholders voted on several key matters. Five Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Additionally, an advisory resolution to approve the compensation of the Company's named executive officers, as disclosed in the April 24, 2026 proxy statement, was approved.
Why It Matters
This 8-K details the outcomes of the annual shareholder meeting, confirming the election of directors, the ratification of the independent auditor, and the approval of executive compensation, which are routine but essential governance matters for investors.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon.”
— From Item 5.07
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Wednesday, June 17, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- low
- Sentiment
- neutral